Pharmacokinetics of Oseltamivir According to Trimester of Pregnancy

Overview

Journal Am J Obstet Gynecol

Publisher Elsevier

Specialty Gynecology & Obstetrics

Date 2011 Apr 16

PMID 21492824

Citations 13

Authors

Laura G Greer

Richard D Leff

Vanessa Laibl Rogers

Scott W Roberts

George H McCracken Jr

George D Wendel Jr

Jeanne S Sheffield

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to determine pharmacokinetic parameters for oseltamivir in all trimesters of pregnancy. Thirty pregnant women, 10 per trimester, who were receiving oseltamivir phosphate (75 mg) were recruited to study first-dose pharmacokinetics. Plasma samples were obtained at 0, 0.5, 1, 2, 4, 8, and 12 hours after the first dose. Samples were analyzed for oseltamivir and oseltamivir carboxylate levels. With the use of a noncompartmental model, we estimated the area-under-the-curve, maximum concentration, time-to-maximum concentration, and half-life. There were no significant differences in the pharmacokinetics of oseltamivir by trimester, except for an increased half-life in the first trimester for oseltamivir phosphate and an increased maximum concentration in the third trimester for oseltamivir carboxylate. The levels of oseltamivir carboxylate that were observed were within the range that was needed to achieve inhibitory concentrations at 50% for pandemic H1N1. The pharmacokinetics of oseltamivir does not change significantly according to trimester of pregnancy.

Citing Articles

Use of antiviral drugs for seasonal influenza: Foundation document for practitioners-Update 2019.

Aoki F, Allen U, Mubareka S, Papenburg J, Stiver H, Evans G J Assoc Med Microbiol Infect Dis Can. 2022; 4(2):60-82.

PMID: 36337743 PMC: 9602959. DOI: 10.3138/jammi.2019.02.08.

Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy.

Chow E, Beigi R, Riley L, Uyeki T Open Forum Infect Dis. 2021; 8(6):ofab138.

PMID: 34189160 PMC: 8232385. DOI: 10.1093/ofid/ofab138.

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Uyeki T, Bernstein H, Bradley J, Englund J, File T, Fry A Clin Infect Dis. 2018; 68(6):e1-e47.

PMID: 30566567 PMC: 6653685. DOI: 10.1093/cid/ciy866.

Antiviral Treatments.

Ison M Clin Chest Med. 2017; 38(1):139-153.

PMID: 28159156 PMC: 7131036. DOI: 10.1016/j.ccm.2016.11.008.

Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.

Pillai V, Han K, Beigi R, Hankins G, Clark S, Hebert M Br J Clin Pharmacol. 2015; 80(5):1042-50.

PMID: 26040405 PMC: 4631177. DOI: 10.1111/bcp.12691.

References

Davies B . Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010; 65 Suppl 2:ii5-ii10. PMC: 2835511. DOI: 10.1093/jac/dkq015. View

Archer B, Cohen C, Naidoo D, Thomas J, Makunga C, Blumberg L . Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill. 2009; 14(42). DOI: 10.2807/ese.14.42.19369-en. View

He G, Massarella J, Ward P . Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 2000; 37(6):471-84. DOI: 10.2165/00003088-199937060-00003. View

Schentag J, Hill G, Chu T, Rayner C . Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol. 2007; 47(6):689-96. DOI: 10.1177/0091270007299761. View

Louie J, Acosta M, Jamieson D, Honein M . Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2009; 362(1):27-35. DOI: 10.1056/NEJMoa0910444. View

Brewster M, Smith J, Dutkowski R, Robson R . Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Vaccine. 2006; 24(44-46):6660-3. DOI: 10.1016/j.vaccine.2006.05.080. View

Bantia S, Parker C, Ananth S, HORN L, Andries K, Chand P . Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother. 2001; 45(4):1162-7. PMC: 90439. DOI: 10.1128/AAC.45.4.1162-1167.2001. View

Rasmussen S, Jamieson D, MacFarlane K, Cragan J, Williams J, Henderson Z . Pandemic influenza and pregnant women: summary of a meeting of experts. Am J Public Health. 2009; 99 Suppl 2:S248-54. PMC: 4504360. DOI: 10.2105/AJPH.2008.152900. View

Widmer N, Meylan P, Ivanyuk A, Aouri M, Decosterd L, Buclin T . Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin Pharmacokinet. 2010; 49(11):741-65. DOI: 10.2165/11534730-000000000-00000. View

10.

Hayden F, Treanor J, Fritz R, Lobo M, Betts R, Miller M . Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999; 282(13):1240-6. DOI: 10.1001/jama.282.13.1240. View

11.

Ng S, Cowling B, Fang V, Chan K, Ip D, Cheng C . Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis. 2010; 50(5):707-14. PMC: 2840043. DOI: 10.1086/650458. View

12.

Siston A, Rasmussen S, Honein M, Fry A, Seib K, Callaghan W . Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010; 303(15):1517-25. PMC: 5823273. DOI: 10.1001/jama.2010.479. View

13.

Jamieson D, Honein M, Rasmussen S, Williams J, Swerdlow D, Biggerstaff M . H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet. 2009; 374(9688):451-8. DOI: 10.1016/S0140-6736(09)61304-0. View

14.

. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(16):433-5. View

15.

Taylor W, Thinh B, Anh G, Horby P, Wertheim H, Lindegardh N . Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One. 2008; 3(10):e3410. PMC: 2565445. DOI: 10.1371/journal.pone.0003410. View

16.

. 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care - New York City, 2009. MMWR Morb Mortal Wkly Rep. 2010; 59(11):321-6. View

17.

Louie J, Acosta M, Winter K, Jean C, Gavali S, Schechter R . Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009; 302(17):1896-902. DOI: 10.1001/jama.2009.1583. View

18.

Worley K, Roberts S, Bawdon R . The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Infect Dis Obstet Gynecol. 2008; 2008:927574. PMC: 2413047. DOI: 10.1155/2008/927574. View

19.

Hewagama S, Walker S, Stuart R, Gordon C, Johnson P, Friedman N . 2009 H1N1 influenza A and pregnancy outcomes in Victoria, Australia. Clin Infect Dis. 2010; 50(5):686-90. DOI: 10.1086/650460. View

20.

Saleeby E, Chapman J, Morse J, Bryant A . H1N1 influenza in pregnancy: cause for concern. Obstet Gynecol. 2009; 114(4):885-891. DOI: 10.1097/AOG.0b013e3181bb44bb. View